SN 25402 | 169527-43-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: SN 25402
• 英文别名: 2-[5-(aminocarbonyl)-N-(2-chloroethyl)-2,4-dinitroanilino]ethyl methanesulfonate；2-[5-(AMINOCARBONYL) (2-chloroethyl)-2, 4-dinitroanilino]ethyl methanesulfonate；2-[5-(Aminocarbonyl)(2-chloroethyl)-2,4-dinitroanilino]ethyl methanesulfonate；2-[5-carbamoyl-N-(2-chloroethyl)-2,4-dinitroanilino]ethyl methanesulfonate
• CAS: 169527-43-9
• 化学式: C₁₂H₁₅ClN₄O₈S
• 分子量: 410.792
• InChiKey: MHOHFBMVOJCKIE-UHFFFAOYSA-N

物化性质

• 沸点：
  610.5±55.0 °C(Predicted)
• 密度：
  1.591±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  190
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  SN 25402 在 lithium bromide 作用下， 以 乙腈 为溶剂， 反应 1.5h， 以68%的产率得到5-[(2-BROMOETHYL) (2-CHLOROETHYL) AMINO]-2,4-dinitrobenzamide
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships for 2,4-Dinitrobenzamide-5-mustards as Prodrugs for the Escherichia coli nfsB Nitroreductase in Gene Therapy

  摘要：

  A series of 2,4-dinitrobenzamide mustards were prepared from 5-chloro-2,4-dinitrobenzoic acid or the corresponding 5-dimesylate mustard as potential prodrugs for gene-directed enzyme prodrug therapy (GDEPT) with the E. coli nfsB nitroreductase (NTR). The compounds, including 32 new examples, were evaluated in four pairs of NTR+ve/-ve cell lines for selective cytotoxicity (IC50 and IC50 ratios), in multicellular layer (MCL) cultures for bystander effects, and for in vivo activity against tumors grown from stably NTR transfected EMT6 and WiDr cells in nude mice. Multivariate regression analysis of the IC50 results was undertaken using a partial least-squares projection to latent structures model. In NTR-ve lines, cytotoxicity correlated positively with logP, negatively with hydrogen bond acceptors (HA) and donors (HD) in the amide side chain, and positively with the reactivity of the less-reactive leaving group of the mustard function, likely reflecting toxicity due to DNA monoadducts. Potency and selectivity for NTR+ve lines was increased by logP and HD, decreased by HA, and was positively correlated with the leaving group efficiency of the more-reactive group, likely reflecting DNA crosslinking. NTR selectivity was greatest for asymmetric chloro/mesylate and bromo/mesylate mustards. Bystander effects in the MCL assay also correlated positively with logP and negatively with leaving group reactivity, presumably reflecting the transcellular diffusion/reaction properties of the activated metabolites. A total of 18 of 22 mustards showed equal or greater bystander efficiencies in MCLs than the aziridinylbenzamide CB 1954, which is currently in clinical trial for NTR-GDEPT. The dibromo and bromomesylate mustards were surprisingly well tolerated in mice. High MTD/IC50 (NTR+ve) ratios translated into curative activity of several compounds against NTR+ve tumors. A bromomesylate mustard showed superior activity against WiDr tumors grown from 1:9 mixtures of NTR+ve and NTR-ve cells, indicating a strong bystander effect in vivo.

  DOI：

  10.1021/jm061062o
• 作为产物：
  描述：

  5-chloro-2,4-dinitrobenzamide 在 三乙胺 、 lithium chloride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 SN 25402
  参考文献：
  名称：

  Synthesis of asymmetric halomesylate mustards with aziridineethanol/alkali metal halides: application to an improved synthesis of the hypoxia prodrug PR-104

  摘要：

  Aromatic asymmetric halomesylate mustards are efficiently prepared by reaction of activated aromatic chlorides with aziridine-ethanol/alkali metal halides, followed by mesylation of the haloalcohol. The reaction conditions are sufficiently mild to be compatible with a range of different substituents and protecting groups, including carboxylate and phosphate esters, and have been used in an improved synthesis of the anticancer bromomesylate mustard PR-104, now in clinical trials. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2007.04.044

文献信息

• [EN] NITROANILINE-BASED ALKYLATING AGENTS AND THEIR USE AS PRODRUGS<br/>[FR] AGENTS D'ALKYLATION A BASE DE NITROANILINE ET LEUR UTILISATION EN TANT QUE PROMEDICAMENTS
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2004033415A1

  公开（公告）日：2004-04-22

  Nitroaniline-based unsymmetrical mustards of the general formula (I) are provided, together with methods of preparation and methods for their use as produgs for gene-dependent enzyme prodrug therapy (GDEPT) and cell ablation therapy in conjuction with nitroreductase enzymes as hypoxia selective cytotoxins and as anticancer agents.

  基于硝基苯胺的不对称芥末化合物，其通用公式为（I），以及它们的制备方法和使用方法，作为基因依赖性酶前药治疗（GDEPT）和与硝基还原酶酶结合的细胞消融治疗的药物，以及作为缺氧选择性细胞毒素和抗癌药物的使用方法。
• Hypoxia-Selective Antitumor Agents. 9. Structure-Activity Relationships for Hypoxia-Selective Cytotoxicity among Analogs of 5-[N,N-Bis(2-chloroethyl)amino]-2,4-dinitrobenzamide
  作者：Brian D. Palmer、William R. Wilson、Graham J. Atwell、Diane Schultz、Xing Z. Xu、William A. Denny

  DOI：10.1021/jm00040a009

  日期：1994.7

  potency and hypoxic selectivity. Modification of the mustard leaving groups or replacement of the carboxamide moiety provided some compounds with superior potency, but only the mixed chloro/mesylate mustard 20 provided a gain in potency relative to solubility while retaining the hypoxic selectivity of 6. These nitrogen mustards did not show the remarkable activity demonstrated by the related aziridine

  为了寻找保留高缺氧性的化合物，已经制备并评估了一系列新型缺氧选择性细胞毒素5- [N，N-双（2-氯乙基）氨基] -2,4-二硝基苯甲酰胺的类似物（6）。选择性但具有增强的效能和/或水溶性。具有可电离或偶极羧酰胺侧链的几种类似物显示出改善的溶解度，但通常具有降低的细胞毒性和低氧选择性。芥菜离去基团的修饰或羧酰胺部分的取代为某些化合物提供了卓越的效力，但只有混合的氯/甲磺酸芥菜碱20相对于溶解度提供了效力，同时保持了6的低氧选择性。相关的氮丙啶7 [CB 1954，5-（N-氮丙啶基）-2 [4-二硝基苯甲酰胺]在Walker 256腺癌细胞中，并且不是DT-diaphorase的有效底物，后者通过Walker细胞中的需氧硝化作用激活了后者。二硝基苯甲酰胺芥末中低氧选择性的变化似乎不是由于该酶对活化的敏感性不同。沃克细胞对单（2-氯乙基）类似物26表现出中等敏感性，但对相关的半芥子味27没有
• Nitroaniline-based alkylating agents and their use as prodrugs
  申请人：Denny Alexander William

  公开号：US20050256191A1

  公开（公告）日：2005-11-17

  Nitroaniline-based unsymmetrical mustards of the general formula (I) are provided, together with methods of preparation and methods for their use as prodrugs for gene-dependent enzyme prodrug therapy (GDEPT) and cell ablation therapy in conjunction with nitroreductase enzymes as hypoxia selective cytotoxins and as anticancer agents.

  提供了基于硝基苯胺的不对称芥子气的一般式（I），以及其制备方法和用作基因依赖性酶前药治疗（GDEPT）和细胞消融治疗的前药的方法，与硝酸还原酶酶一起使用作为缺氧选择性细胞毒素和抗癌剂。
• Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom
  申请人：Atwell Graham John

  公开号：US20100121091A1

  公开（公告）日：2010-05-13

  The invention relates to methods of preparing compounds of formula (II) wherein Z represents —OR 1 or N(R 2 )R 2a —, where R 1 is lower alkylene (C 1 -C 6 ), R 2 is lower alkyl or H and R 2a is lower alkylene (C 1 -C 6 ) or H; Q is absent when R 2a is H and is otherwise selected from the group consisting of H, —OH and protected forms of —OH; one of X and Y is halogen and the other is —OSO 2 R 3 , where R 3 is selected from the group consisting of lower alkyl (C 1 -C 6 ), phenyl and CH 2 phenyl. The method comprises the steps of: (a) reacting a compound of formula (I) with aziridineethanol or a 2-[(2-haloethyl)amino]ethanol in the presence of a metal halide, to form a compound of the formula (III) wherein one of X and E is halogen and the other is hydroxy, and (b) reacting the compound of formula (III) with an alkyl- or arylsulfonyl halide or alkyl- or arylsulfonyl anhydride to obtain a compound of the formula (II). The invention also relates to methods of preparing compounds of formula (IV) from the compounds of formula (II) so obtained, and to novel compounds of formula (IIb) useful as intermediates in these methods.

  本发明涉及制备式（II）化合物的方法，其中Z代表—OR1或N（R2）R2a—，其中R1为低碳链（C1-C6），R2为低碳基或H，R2a为低碳链（C1-C6）或H；当R2a为H时，Q不存在，否则Q选择自羟基（—OH）和保护的羟基形式；X和Y中的一个是卤素，另一个是—OSO2R3，其中R3选择自低碳基（C1-C6）、苯基和CH2苯基。该方法包括以下步骤：（a）在金属卤化物的存在下，将式（I）化合物与环氧丙胺乙醇或2-[(2-卤基乙基)氨基]乙醇反应，形成式（III）化合物，其中X和E中的一个是卤素，另一个是羟基，（b）将式（III）化合物与烷基或芳基磺酰卤或烷基或芳基磺酰酐反应，得到式（II）化合物。本发明还涉及从所得到的式（II）化合物制备式（IV）化合物的方法，以及作为这些方法中间体的新型式（IIb）化合物。
• WO2008/30112
  申请人：——

  公开号：——

  公开（公告）日：——